questionsmedicales.fr
Thérapeutique
Hyperthermie provoquée
Hyperthermie provoquée : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hyperthermie provoquée : Questions médicales les plus fréquentes",
"headline": "Hyperthermie provoquée : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hyperthermie provoquée : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-20",
"dateModified": "2025-03-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hyperthermie provoquée"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Thérapeutique",
"url": "https://questionsmedicales.fr/mesh/D013812",
"about": {
"@type": "MedicalCondition",
"name": "Thérapeutique",
"code": {
"@type": "MedicalCode",
"code": "D013812",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Psammothérapie",
"alternateName": "Ammotherapy",
"url": "https://questionsmedicales.fr/mesh/D000646",
"about": {
"@type": "MedicalCondition",
"name": "Psammothérapie",
"code": {
"@type": "MedicalCode",
"code": "D000646",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.565.020"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Diathermie",
"alternateName": "Diathermy",
"url": "https://questionsmedicales.fr/mesh/D003972",
"about": {
"@type": "MedicalCondition",
"name": "Diathermie",
"code": {
"@type": "MedicalCode",
"code": "D003972",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.565.280"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Ultrasonothérapie",
"alternateName": "Ultrasonic Therapy",
"url": "https://questionsmedicales.fr/mesh/D014464",
"about": {
"@type": "MedicalCondition",
"name": "Ultrasonothérapie",
"code": {
"@type": "MedicalCode",
"code": "D014464",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.565.280.945"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Chimiothérapie hyperthermique intrapéritonéale",
"alternateName": "Hyperthermic Intraperitoneal Chemotherapy",
"url": "https://questionsmedicales.fr/mesh/D000084262",
"about": {
"@type": "MedicalCondition",
"name": "Chimiothérapie hyperthermique intrapéritonéale",
"code": {
"@type": "MedicalCode",
"code": "D000084262",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.565.370"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Bain de vapeur",
"alternateName": "Steam Bath",
"url": "https://questionsmedicales.fr/mesh/D029002",
"about": {
"@type": "MedicalCondition",
"name": "Bain de vapeur",
"code": {
"@type": "MedicalCode",
"code": "D029002",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.565.640"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hyperthermie provoquée",
"alternateName": "Hyperthermia, Induced",
"code": {
"@type": "MedicalCode",
"code": "D006979",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mohammad-Amin Abdollahifar",
"url": "https://questionsmedicales.fr/author/Mohammad-Amin%20Abdollahifar",
"affiliation": {
"@type": "Organization",
"name": "Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: abdollahima@sbmu.ac.ir."
}
},
{
"@type": "Person",
"name": "Abbas Aliaghaei",
"url": "https://questionsmedicales.fr/author/Abbas%20Aliaghaei",
"affiliation": {
"@type": "Organization",
"name": "Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran."
}
},
{
"@type": "Person",
"name": "Jon E Sprague",
"url": "https://questionsmedicales.fr/author/Jon%20E%20Sprague",
"affiliation": {
"@type": "Organization",
"name": "The Ohio Attorney General's Center for the Future of Forensic Science, USA. Electronic address: jesprag@bgsu.edu."
}
},
{
"@type": "Person",
"name": "Amir Raoofi",
"url": "https://questionsmedicales.fr/author/Amir%20Raoofi",
"affiliation": {
"@type": "Organization",
"name": "Leishmaniasis Research Center, Department of Anatomy, Sabzevar University of Medical Sciences, Sabzevar, Iran."
}
},
{
"@type": "Person",
"name": "Shabnam Abdi",
"url": "https://questionsmedicales.fr/author/Shabnam%20Abdi",
"affiliation": {
"@type": "Organization",
"name": "Department of Anatomical Sciences & Cognitive Neuroscience, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data.",
"datePublished": "2024-05-31",
"url": "https://questionsmedicales.fr/article/38820324",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0304649"
}
},
{
"@type": "ScholarlyArticle",
"name": "A novel",
"datePublished": "2022-09-23",
"url": "https://questionsmedicales.fr/article/36213261",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2022.1008800"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bone Deformities and Kidney Failure: Coincidence of PHEX-Related Hypophosphatemic Rickets and m.3243A>G Mitochondrial Disease.",
"datePublished": "2022-08-02",
"url": "https://questionsmedicales.fr/article/35916905",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00223-022-01010-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Genetic Evidence for a Causal Role of Serum Phosphate in Coronary Artery Calcification: The Rotterdam Study.",
"datePublished": "2022-07-29",
"url": "https://questionsmedicales.fr/article/35904204",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1161/JAHA.121.023024"
}
},
{
"@type": "ScholarlyArticle",
"name": "First-year mortality in incident dialysis patients: results of the Peridialysis study.",
"datePublished": "2022-06-27",
"url": "https://questionsmedicales.fr/article/35761193",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12882-022-02852-1"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Thérapeutique",
"item": "https://questionsmedicales.fr/mesh/D013812"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hyperthermie provoquée",
"item": "https://questionsmedicales.fr/mesh/D006979"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hyperthermie provoquée - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hyperthermie provoquée",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hyperthermie provoquée",
"description": "Comment diagnostiquer l'hyperthermie provoquée ?\nQuels tests sont utilisés pour confirmer l'hyperthermie ?\nQuels signes cliniques indiquent une hyperthermie ?\nL'hyperthermie est-elle toujours dangereuse ?\nComment différencier l'hyperthermie de la fièvre ?",
"url": "https://questionsmedicales.fr/mesh/D006979?mesh_terms=Hyperphosphatemia&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hyperthermie provoquée",
"description": "Quels sont les symptômes de l'hyperthermie provoquée ?\nL'hyperthermie provoquée cause-t-elle des douleurs ?\nPeut-on avoir des troubles de la conscience ?\nY a-t-il des signes cutanés associés ?\nL'hyperthermie provoquée affecte-t-elle la respiration ?",
"url": "https://questionsmedicales.fr/mesh/D006979?mesh_terms=Hyperphosphatemia&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hyperthermie provoquée",
"description": "Comment prévenir l'hyperthermie provoquée ?\nLes vêtements influencent-ils l'hyperthermie ?\nFaut-il surveiller la température corporelle ?\nLes pauses sont-elles importantes ?\nL'alimentation joue-t-elle un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D006979?mesh_terms=Hyperphosphatemia&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hyperthermie provoquée",
"description": "Comment traiter l'hyperthermie provoquée ?\nDes médicaments sont-ils nécessaires ?\nQuelle est l'importance de l'hydratation ?\nQuand faut-il consulter un médecin ?\nLe repos est-il recommandé ?",
"url": "https://questionsmedicales.fr/mesh/D006979?mesh_terms=Hyperphosphatemia&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hyperthermie provoquée",
"description": "Quelles complications peuvent survenir ?\nL'hyperthermie peut-elle être mortelle ?\nQuels organes sont les plus affectés ?\nDes séquelles peuvent-elles persister ?\nComment éviter les complications graves ?",
"url": "https://questionsmedicales.fr/mesh/D006979?mesh_terms=Hyperphosphatemia&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hyperthermie provoquée",
"description": "Qui est le plus à risque d'hyperthermie ?\nL'exercice augmente-t-il le risque ?\nLes médicaments influencent-ils le risque ?\nL'humidité joue-t-elle un rôle ?\nLe surpoids est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D006979?mesh_terms=Hyperphosphatemia&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'hyperthermie provoquée ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation clinique et la mesure de la température corporelle."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer l'hyperthermie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des évaluations physiologiques peuvent être réalisés."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une hyperthermie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent une température élevée, des frissons et une confusion mentale."
}
},
{
"@type": "Question",
"name": "L'hyperthermie est-elle toujours dangereuse ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, elle peut être contrôlée, mais nécessite une surveillance."
}
},
{
"@type": "Question",
"name": "Comment différencier l'hyperthermie de la fièvre ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hyperthermie est causée par des facteurs externes, alors que la fièvre est une réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de l'hyperthermie provoquée ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des nausées, des vertiges, des maux de tête et une confusion."
}
},
{
"@type": "Question",
"name": "L'hyperthermie provoquée cause-t-elle des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des douleurs musculaires et des crampes."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des troubles de la conscience ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles de la conscience peuvent survenir en cas d'hyperthermie sévère."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des rougeurs ou des éruptions cutanées peuvent apparaître en cas d'hyperthermie."
}
},
{
"@type": "Question",
"name": "L'hyperthermie provoquée affecte-t-elle la respiration ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner une respiration rapide et superficielle."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hyperthermie provoquée ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez les environnements chauds et hydratez-vous régulièrement lors d'activités physiques."
}
},
{
"@type": "Question",
"name": "Les vêtements influencent-ils l'hyperthermie ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, porter des vêtements légers et respirants aide à prévenir l'hyperthermie."
}
},
{
"@type": "Question",
"name": "Faut-il surveiller la température corporelle ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, surveiller la température est essentiel lors d'activités à risque."
}
},
{
"@type": "Question",
"name": "Les pauses sont-elles importantes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, prendre des pauses régulières lors d'activités physiques intenses est crucial."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée aide à maintenir une bonne régulation thermique."
}
},
{
"@type": "Question",
"name": "Comment traiter l'hyperthermie provoquée ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut le refroidissement du corps et l'hydratation adéquate."
}
},
{
"@type": "Question",
"name": "Des médicaments sont-ils nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments peuvent être administrés pour soulager les symptômes associés."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de l'hydratation ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hydratation est cruciale pour prévenir des complications graves liées à l'hyperthermie."
}
},
{
"@type": "Question",
"name": "Quand faut-il consulter un médecin ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez un médecin si les symptômes persistent ou s'aggravent malgré le traitement."
}
},
{
"@type": "Question",
"name": "Le repos est-il recommandé ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le repos est essentiel pour permettre au corps de récupérer."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des coups de chaleur, des défaillances organiques et des convulsions."
}
},
{
"@type": "Question",
"name": "L'hyperthermie peut-elle être mortelle ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une hyperthermie sévère non traitée peut entraîner la mort."
}
},
{
"@type": "Question",
"name": "Quels organes sont les plus affectés ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le cerveau, le cœur et les reins sont particulièrement vulnérables à l'hyperthermie."
}
},
{
"@type": "Question",
"name": "Des séquelles peuvent-elles persister ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des séquelles neurologiques peuvent persister après une hyperthermie sévère."
}
},
{
"@type": "Question",
"name": "Comment éviter les complications graves ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement rapide et approprié est essentiel pour éviter les complications graves."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque d'hyperthermie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées, les enfants et celles avec des maladies chroniques sont plus à risque."
}
},
{
"@type": "Question",
"name": "L'exercice augmente-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice intense dans des environnements chauds augmente le risque d'hyperthermie."
}
},
{
"@type": "Question",
"name": "Les médicaments influencent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent altérer la régulation thermique et augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'humidité joue-t-elle un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une humidité élevée augmente le risque d'hyperthermie en réduisant l'évaporation de la sueur."
}
},
{
"@type": "Question",
"name": "Le surpoids est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le surpoids peut augmenter le risque d'hyperthermie en réduisant l'efficacité de la thermorégulation."
}
}
]
}
]
}
Hyperphosphatemia and hyperparathyroidism are common in end-stage kidney disease and are associated with poor outcomes. In addition to adequate dialysis, medications are usually required for optimum c...
This 10-year retrospective cohort study examined the differences in mineral outcomes between two healthcare programs in maintenance hemodialysis patients. The differences in serum calcium, phosphate, ...
714 patients were included in the analyses (full cohort). Of these patients, 563 required at least one type of medication to control MBD (MBD medication subgroup). Serum calcium, phosphate, and the pr...
Patients under the healthcare program that did not cover the use of NCBPBs and calcimimetics showed higher serum calcium and phosphate levels and a more rapid progression of hyperparathyroidism. The d...
Hyperphosphatemic familial tumoral calcinosis (HFTC) is a rare disease characterized by hyperphosphatemia and ectopic calcification, predominantly at periarticular locations. This study was performed ...
The three subjects (two male and one female) were aged 30, 25 and 15 years, respectively. The clinical features, histopathological findings, and outcomes of three subjects with HFTC were retrospective...
All subjects had hyperphosphatemia and elevated calcium-phosphorus product. Calcinosis positions included the left shoulder, left index finger, and right hip. Bone and joint damage were present in two...
We identified a novel...
X-linked hypophosphatemic rickets (XLH) and m.3243A>G mitochondrial disease share several clinical findings, including short stature, hearing impairment (HI), nephropathy, and hypertension. Here, w...
Background Hyperphosphatemia has been associated with coronary artery calcification (CAC) mostly in chronic kidney disease, but the association between phosphate levels within the normal phosphate ran...
Controversy surrounds which factors are important for predicting early mortality after dialysis initiation (DI). We investigated associations of predialysis course and circumstances affecting planning...
Among 1580 patients participating in the Peridialysis study, a study of causes and timing of DI, we registered features of predialysis course, clinical and biochemical data at DI, incidence of unplann...
First-year mortality was 19.33%. Independent factors predicting death were high age, comorbidity, clinical contraindications to PD or HD, suboptimal DI, high eGFR, low serum albumin, hyperphosphatemia...
First-year mortality in incident dialysis patients was in addition to high age and comorbidity, associated with clinical contraindications to PD or HD, clinical symptoms, hyperphosphatemia, inflammati...
There was limited research on the epidemiology of hyperphosphatemia in early-stage chronic kidney disease (CKD) patients. We aimed to explore the clinical characteristics and prognostic value of hyper...
We enrolled adult patients with CKD stages 1-2 from 24 regional central hospitals across China. Hyperphosphatemia was defined as a serum phosphate level exceeding 1.45 mmol/L. The study outcomes inclu...
Among 99,266 patients with CKD stages 1-2 across China, the prevalence of hyperphosphatemia was 8.3%. The prevalence of hyperphosphatemia was increased with the level of urinary protein and was higher...
Hyperphosphatemia was not rare in patients with CKD stages 1-2 and was associated with an increased risk of mortality. Clinicians should closely monitor serum phosphorus levels in patients with CKD, e...
Serum phosphorus management is important for patients with chronic kidney disease on dialysis to reduce the risk of hyperparathyroidism and ectopic vascular calcification. Phosphate binders (PBs) cont...
This study evaluated the efficacy and safety of tenapanor treatment with up-titration when added to PBs among Japanese hemodialysis patients with hyperphosphatemia poorly controlled by PBs alone. In t...
The least squares mean change from baseline to week 8 in serum phosphorus level was -0.24 and -2.00 mg/dl in the placebo and tenapanor groups, respectively, with a statistically significant difference...
Tenapanor added to PBs improved serum phosphorus levels that could not previously be controlled by PBs alone, and no new safety concerns were raised....
Phosphate binders are the main treatment for hyperphosphatemia in patients with chronic kidney disease, and iron-based phosphate binders have been used with increasing frequency in recent years. This ...
Cardiovascular calcification can occur in vascular and valvular structures and is commonly associated with calcium deposition and tissue mineralization leading to stiffness and dysfunction. Patients w...
Malnutrition is a serious problem that influences morbidity, mortality, functional activity, and quality of life in patients with chronic kidney disease (CKD). However, there has not been much researc...
This prospective cohort study (n = 360) involved non-dialysis CKD patients with index estimated glomerular filtration rate (eGFR) between the range of 15-89 ml/min/1.73 m...
Around 244 (67.8%) of patients have experienced a fast decline in kidney function. In the malnourished group, systolic blood pressure and hyperphosphatemia were observed to have increased hazards for ...
Fast CKD progression was observed to be more common in malnourished patients. Systolic blood pressure and hyperphosphatemia were recognized as potential predictors of fast CKD progression. Moreover, m...